Sign Up to like & get
recommendations!
1
Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz437.011
Abstract: Abstract Background Afatinib is indicated for the treatment of EGFR mutation-positive (M+) non-small cell lung cancer (NSCLC). LUX-Lung trials have demonstrated that afatinib significantly improved progression-free survival (PFS) compared with chemotherapy. We report results from…
read more here.
Keywords:
afatinib korean;
first line;
line afatinib;
korean patients ... See more keywords